Xenon Pharmaceuticals Inc logo

XENE

Xenon Pharmaceuticals Inc

$36.4

Earnings Summary

Revenue
$8.77Mn
Net Profits
$-19.67Mn
Net Profit Margins
-224.39%

Highlights

Revenue:

Xenon Pharmaceuticals Inc’s revenue jumped 101.15% since last year same period to $8.77Mn in the Q1 2022. On a quarterly growth basis, Xenon Pharmaceuticals Inc has generated 134.57% jump in its revenue since last 3-months.

Net Profits:

Xenon Pharmaceuticals Inc’s net profit fell -24.78% since last year same period to $-19.67Mn in the Q1 2022. On a quarterly growth basis, Xenon Pharmaceuticals Inc has generated 23.06% jump in its net profits since last 3-months.

Net Profit Margins:

Xenon Pharmaceuticals Inc’s net profit margin jumped 37.97% since last year same period to -224.39% in the Q1 2022. On a quarterly growth basis, Xenon Pharmaceuticals Inc has generated 67.2% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Xenon Pharmaceuticals Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.48
EPS Estimate Current Year
-0.48

Highlights

EPS Estimate Current Quarter:

Xenon Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -0.48 - a -17.07% fall from last quarter’s estimates.

EPS Estimate Current Year:

Xenon Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.48.

Key Ratios

Key ratios of the Xenon Pharmaceuticals Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.35
Return on Assets (ROA)
-0.13
Return on Equity (ROE)
-0.22
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Xenon Pharmaceuticals Inc’s earning per share (EPS) jumped 16.67% since last year same period to -0.35 in the Q1 2022. This indicates that the Xenon Pharmaceuticals Inc has generated 16.67% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Xenon Pharmaceuticals Inc’s return on assets (ROA) stands at -0.13.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Xenon Pharmaceuticals Inc’s return on equity (ROE) stands at -0.22.

Dividend Per Share (DPS):

Xenon Pharmaceuticals Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-10
-0.41
-0.35
14.63%

Company Information

Xenon is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. The Company is advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy.

Organisation
Xenon Pharmaceuticals Inc
Headquarters
Burnaby, British Columbia, Canada
Employees
129
Industry
Health Technology
CEO
Simon Pimstone